New Antibody-Drug conjugate takes aim at tough leukemias
NCT ID NCT06359002
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This first-in-human trial tests BYON4413, an antibody-drug conjugate designed to target and kill cancer cells in people with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic neoplasms (MDS). The study involves 16 participants and aims to check safety, how the drug moves through the body, and any early signs of effectiveness. It is a small, early-stage trial, so results will help decide if larger studies are warranted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BYON4413 (an antibody-drug conjugate given by IV infusion)
- What this could lead to
- If it works, this could point toward a new treatment option for people with hard-to-treat AML or MDS.
- What could go wrong
- This is a very early, small trial (16 people) focused on safety, so it may not show strong benefit. Side effects are unknown and could be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED / REFRACTORY AML are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Het Ziekenhuisnetwerk Antwerpen
Antwerp, Belgium
-
Hospital Clinic de Barcelona
Barcelona, Spain
-
Hospital San Pedro de Alcantara
Cáceres, Spain
-
Hospital Universitario de Salamanca
Salamanca, Spain
-
Hospital Universitario y Politecnico La Fe
Valencia, Spain
-
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
-
Institut Catala d'Oncologia
Badalona, Spain
-
UZ Leuven
Leuven, Belgium
-
Universitair Medisch Centrum Groningen
Groningen, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.